Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study

Bone Marrow Transplantation

Volumn 22, Issue 8, 1998, Pages 743-750

  Montagna, D ^a,b   Locatelli, F ^a   Calcaterra, V ^a   Comoli, P ^a   Moretta, A ^a   Giorgiani, G ^a   Zecca, M ^a   Bonetti, F ^a   Giraldi, E ^a   Rondini, G ^a   Maccario, R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Bone marrow transplantation; CTL; Graft versus host disease; Graft versus leukaemia; Leukaemia relapse

Indexed keywords

HLA ANTIGEN CLASS 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SIBLING; STEM CELL; T LYMPHOCYTE SUBPOPULATION;

EID: 0031736563     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701419     Document Type: Article

References (44)

1. Treleaven J, Barrett J. Bone Marrow Transplantation in Practice. Churchill Livingstone: Edinburgh, 1992, p 399.
2. Sykes M, Romick ML, Hoyles KA, Sachs DH. Interleukin-2 prevents graft-versus-host-disease without diminishing the graft-versus-leukemia effect of allogeneic lymphocytes. Proc Natl Acad Sci USA 1990:87: 5633-3637.
3. Truitt RL, Atasoylu AA. Impact of pretransplant conditioning and donor T cells on chimerism, graft-versus-host disease, graft-versus-leukemia reactivity, and tolerance after bone marrow transplantation. Blood 1991; 77: 2515-2523.
4. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother 1990; 31: 236-242.
5. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. New Engl J Med 1979; 300: 1068-1073.
6. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
7. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
8. Marmont AM, Horowitz MM, Gale RP el al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
9. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997; 157: 125-140.
10. Falkenburg JHF, Smit WM, Willemze R. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev 1997; 157: 223-230.
11. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF. Generation of leukemia-re active cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
12. + minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995; 96: 877-883.
13. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-2828.
14. + progenitor cells. Blood 1997; 90 (Suppl. 1): 548a.
15. Sosman JA, Oettel KR, Hank JA et al. Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantion 1989; 48: 486-495.
16. Salomo M, Steinmann J, Glass B et al. Leukemia-specific allogeneic donor T cells: quantification by limiting dilution assay. Bone Marrow Transplant 1995; 15: 179-186.
17. Weiss L, Lubin I, Factorowich I et al. Effective graft-versus-leukemia effect independent of graft-versus-host disease after T cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. J Immunol 1994; 153: 2562-2567.
18. + T cell activity. J Immunol 1993; 150: 197-205.
19. Johnson BD, Truitt RL. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995; 85: 3302-3312.
20. 2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol 1995; 154; 5542-5554.
21. Jiang JYZ, Mavroudis DA, Dermlne S et al. Preferential usage of T cell receptor (TCR) Vβ by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graftversus-leukemia effect from graft-versus-host disease. Bone Marrow Transplant 1997; 19: 899-903.
22. Slavin S, Ackerstein A, Naparstek E et al. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD? Bane Marrow Transplant 1990; 6: 155-161.
23. van Lochern E, de Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
24. - cytotoxic T cell clones specific for leukemic blasts in children with acute leukemia. Cancer Res 1995; 55: 3835-3839.
25. + human cytotoxic T lymphocytes. J Immunol 1993; 150: 1437-1445.
26. Sharrock CEM, Kaminski E, Man E. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today 1990; 11: 281-286.
27. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987; 17: 105-111.
28. + T cells specific for conserved regions of human immunodeficiency virus glycoprotein gp 120 in human immunized with a recombinant envelope protein. Proc Natl Acad Sci USA 1990; 87: 6136-6140.
29. Anichini A, Fossati G, Parmiani G. Clonal analysis of the cytolytic T cell response to human tumors. Immunol Today 1987; 8: 385-389.
30. Guinan EC, Gribben JG, Boussiotis VA et al. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-3282.
31. + T-cell line with potent in vivo graft-versus-leukemia properties. Blood 1997; 89: 3477-3485.
32. Lenschow DJ, Walunas TL, Bluestone JA. GD28/B7 system of T cell costimulation, Annu Rev Immunol 1996; 14: 233258.
33. Cardoso AA, Schultze JL, Boussiotis VA et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41-48.
34. Dermime S, Mavroudis D, Jiang Y-Z et al. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 19: 989-999.
35. Choudhury A, Gajewski JL, Liang JC et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89: 1133-1142.
36. Kaufmann SHE. γ/δ and other unconventional T lymphocytes: what do they see and what do they do? Proc Natl Acad Sci USA 1996; 93: 2272-2279.
37. Zocchi MR, Ferrarini M, Rugarli C. Selective lysis of the autologous tumor by δTCS1+ γδ tumor infiltrating lymphocytes from human lung carcinoma. Eur J Immunol 1990; 20: 2685-2689.
38. Douval M, Yotnda P, Benussan A et al. Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia. Leukemia 1995; 9: 863-868.
39. Choudhary A, Davodeau F, Moreau A et al. Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lymphocytes from renal carcinoma. J Immunol 1995; 154: 3932-3940.
40. Gambacorti-Passerini C, Grignani F et al. Human CD4 lymphocytes recognize a peptide presenting the fusion region of the hybrid protein PML/RARa present in acute promyelocytic leukemia cells. Blood 1993; 81: 1369-1379.
41. Brenner MK, Heslop HE. Graft-versus-host-reactions and bone marrow transplantation. Curr Opin Immunol 1991; 3: 752-761.
42. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-2457.
43. Barren AJ, Malkovska V. Graft-versus-leukemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754-761.
44. Malkovska V, Cigel F, Sondel PM, Parker K. Synthetic peptides derived from the CD19 protein bind to the class I HLA-A2.1. Blood 1995; 86 (Suppl.l): 157a.